226 related articles for article (PubMed ID: 21955085)
21. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
[TBL] [Abstract][Full Text] [Related]
22. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
23. Combination adjuvants: the next generation of adjuvants?
Mutwiri G; Gerdts V; van Drunen Littel-van den Hurk S; Auray G; Eng N; Garlapati S; Babiuk LA; Potter A
Expert Rev Vaccines; 2011 Jan; 10(1):95-107. PubMed ID: 21162624
[TBL] [Abstract][Full Text] [Related]
24. Cationic liposomes as vaccine adjuvants.
Christensen D; Korsholm KS; Andersen P; Agger EM
Expert Rev Vaccines; 2011 Apr; 10(4):513-21. PubMed ID: 21506648
[TBL] [Abstract][Full Text] [Related]
25. Vaccine adjuvant properties of probiotic bacteria.
Licciardi PV; Tang ML
Discov Med; 2011 Dec; 12(67):525-33. PubMed ID: 22204769
[TBL] [Abstract][Full Text] [Related]
26. Adjuvants and autoimmunity.
Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
[TBL] [Abstract][Full Text] [Related]
27. TLR4 agonists as immunomodulatory agents.
Alderson MR; McGowan P; Baldridge JR; Probst P
J Endotoxin Res; 2006; 12(5):313-9. PubMed ID: 17059695
[TBL] [Abstract][Full Text] [Related]
28. Towards tailored vaccine delivery: needs, challenges and perspectives.
Amorij JP; Kersten GF; Saluja V; Tonnis WF; Hinrichs WL; Slütter B; Bal SM; Bouwstra JA; Huckriede A; Jiskoot W
J Control Release; 2012 Jul; 161(2):363-76. PubMed ID: 22245687
[TBL] [Abstract][Full Text] [Related]
29. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
[TBL] [Abstract][Full Text] [Related]
30. Contemporary approaches to designing and evaluating vaccines against Chlamydia.
Igietseme JU; Eko FO; Black CM
Expert Rev Vaccines; 2003 Feb; 2(1):129-46. PubMed ID: 12901604
[TBL] [Abstract][Full Text] [Related]
31. Virus-like particle vaccines and adjuvants: the HPV paradigm.
Buonaguro FM; Tornesello ML; Buonaguro L
Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
[TBL] [Abstract][Full Text] [Related]
32. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
Lawson LB; Norton EB; Clements JD
Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
[TBL] [Abstract][Full Text] [Related]
33. The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 1.
Jones SD
IDrugs; 2010 Oct; 13(10):689-91. PubMed ID: 20878588
[TBL] [Abstract][Full Text] [Related]
34. Immunity in response to particulate antigen-delivery systems.
Storni T; Kündig TM; Senti G; Johansen P
Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
[TBL] [Abstract][Full Text] [Related]
35. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin M as a vaccine adjuvant.
Ilag LL
Med Hypotheses; 2011 Oct; 77(4):473-8. PubMed ID: 21723670
[TBL] [Abstract][Full Text] [Related]
37. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
De Magistris MT
Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
[TBL] [Abstract][Full Text] [Related]
38. Systematic identification of small molecule adjuvants.
Flower DR
Expert Opin Drug Discov; 2012 Sep; 7(9):807-17. PubMed ID: 22724523
[TBL] [Abstract][Full Text] [Related]
39. The path to a successful vaccine adjuvant--'the long and winding road'.
O'Hagan DT; De Gregorio E
Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916
[TBL] [Abstract][Full Text] [Related]
40. Adjuvants in perspective.
Vogel FR
Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
